Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | DDX3X | O00571 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CDC7 | O00311 | 3/20 | 0.46 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.46 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | IRS1 | P35568 | 1/20 | 0.45 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | RARA | P10276 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25398170 | 0.88 | TRPM8 (0.60) | TRPM8KDM4ERAB9ADDX3XALDH1A1 | |
| SCHEMBL2179717 | 0.88 | TRPM8 (0.58) | TRPM8KDM4ERAB9ADDX3XALDH1A1 | |
| SCHEMBL17212202 | 0.87 | CDC7 (0.62) | KDM4EALDH1A1CDC7DBF4GAA | |
| SCHEMBL22042122 | 0.84 | KDM4E (0.48) | TRPM8KDM4ERAB9ADDX3XALDH1A1 | |
| SCHEMBL25398284 | 0.82 | ALDH1A1 (0.45) | TRPM8KDM4ERAB9ADDX3XALDH1A1 | |
| SCHEMBL30579925 | 0.82 | ALDH1A1 (0.45) | TRPM8KDM4ERAB9ADDX3XALDH1A1 | |
| SCHEMBL25399886 | 0.81 | TRPM8 (0.40) | TRPM8KDM4ERAB9ADDX3XALDH1A1 | |
| SCHEMBL22617521 | 0.80 | CDC7 (0.42) | TRPM8KDM4ERAB9ADDX3XALDH1A1 | |
| SCHEMBL30096283 | 0.80 | KDM4E (0.56) | KDM4ERAB9ADDX3XALDH1A1SMN1; SMN2 | |
| SCHEMBL1638585 | 0.79 | CDC7 (0.56) | KDM4ERAB9AALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197363-A1 | THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME | CUREVERSE INCORPORATED (KR) | 2025-06-19 | — | — | US | disclosed |
| EP-4495106-A1 | THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2025-01-22 | — | — | EP | disclosed |
| CN-119212981-A | Thiadiazole compound and pharmaceutical composition for preventing or treating inflammatory diseases comprising the same | 财团法人 大邱庆北尖端医疗产业振兴财团 | 2024-12-27 | — | — | CN | disclosed |
| WO-2023177146-A1 | THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME | 재단법인 대구경북첨단의료산업진흥재단 | 2023-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197363-A1 | THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME | PPARD, PPARG, PPARA | TRPM8 1838/4885KDM4E 3471/4885RAB9A 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.